

IMPORTANT PARTICIPANT INFORMATION: A NEW CLINICAL RESEARCH STUDY IN PLAQUE PSORIASIS IS NOW ENROLLING



The **ABP 501 Switching Study** is a clinical research study for men and women with moderate to severe plaque psoriasis.

Who can take part?*

Men and women who:

- are between 18 and 75 years of age
- have had plaque psoriasis for at least 6 months.



Why is the study taking place?

The purpose of this study is to find out whether an investigational “**switching**” medication routine (**A**) can safely and effectively be substituted in place of a **non-switching** medication routine (**B**).

A - participants **switch** between an approved treatment for plaque psoriasis (**adalimumab**; brand name Humira®) and an investigational drug (**ABP 501**).

B - participants receive **only adalimumab**.



Who will be joining the study?

Approximately **414 participants** are expected to take part at study centers across the globe, including in **North America** and **Europe**.



What does the study involve?

Participants will receive **adalimumab** for the **first 12 weeks** of the study. At Week 12, those whose psoriasis has shown meaningful improvement may continue on in the study. These participants will:

- Be randomly assigned to either the **switching** or **non-switching** medication routine for a further 16 weeks
- Attend regular scheduled visits at the study center
- Undergo medical procedures and tests during these visits.



For further information about the **ABP 501 Switching Study**, please contact the study team as follows:

Name: **Bellaire Dermatology Associates**

Telephone: **713-661-4383**

Email: **clinicaltrials@bellairedermatology.com**

*There are other criteria that you will need to meet to qualify for the **ABP 501 Switching Study**; the study team will discuss these with you. By contacting us we can determine if the study may be an option for you.

ABP 501
switching study